Related Experiment Video
Updated: Feb 9, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Role of Purine Biosynthesis in Persistent Methicillin-Resistant Staphylococcus aureus Infection
Liang Li1, Wessam Abdelhady1, Niles P Donegan2
1Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance.
Abstract:
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) represents an important subset of S. aureus endovascular infections. In this study, we investigated potential genetic mechanisms underlying the persistent outcomes. Compared with resolving bacteremia (RB) isolates (defined as isolates associated with negative results of blood cultures 2-4 days after initiation of therapy), PB strains (defined as isolates associated with positive results of blood cultures ≥7 days after initiation of therapy) had significantly earlier onset activation of key virulence regulons and structural genes (eg, sigB, sarA, sae, and cap5), higher expression of purine biosynthesis genes (eg, purF), and faster growth rates, with earlier entrance into stationary phase. Importantly, an isogenic strain set featuring a wild-type MRSA isolate, a purF mutant strain, and a purF-complemented strain and use of strategic purine biosynthesis inhibitors implicated a causal relationship between purine biosynthesis and the in vivo persistent outcomes. These observations suggest that purine biosynthesis plays a key role in the outcome of PB and may represent a new target for enhanced efficacy in treating life-threatening MRSA infections.
Insights
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is linked to earlier virulence gene activation and faster growth. Purine biosynthesis is a key factor in persistent MRSA infections, offering a potential new therapeutic target.
Area of Science:
- Microbiology
- Infectious Diseases
- Genetics
Background:
- Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) is a critical clinical challenge.
- Understanding the genetic underpinnings of PB is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the genetic mechanisms associated with persistent MRSA bacteremia.
- To identify potential therapeutic targets for improving outcomes in PB.
Main Methods:
- Comparative analysis of gene expression in persistent bacteremia (PB) versus resolving bacteremia (RB) isolates.
- Assessment of virulence regulons, purine biosynthesis genes (e.g., purF), and growth rates.
- Utilizing isogenic MRSA strains (wild-type, purF mutant, purF-complemented) and purine biosynthesis inhibitors.
Main Results:
- PB strains exhibited earlier activation of virulence genes (sigB, sarA, sae, cap5) and higher expression of purine biosynthesis genes (purF).
- PB strains demonstrated faster growth rates and earlier entry into stationary phase.
- Experimental manipulation of purine biosynthesis confirmed its causal role in persistent MRSA bacteremia.
Conclusions:
- Purine biosynthesis is a critical factor contributing to the persistence of MRSA bacteremia.
- Targeting purine biosynthesis pathways presents a novel strategy for treating persistent MRSA infections.
Related Concept Videos
Biosynthesis in Bacteria
Biosynthesis of Polysaccharides
Biosynthesis of Lipids
Biosynthesis of Nucleic Acids
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Resistivity

